KORU Medical (KRMD) Director Buys 3,916 Shares at $3.83

Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share.

Accepted by SEC EDGAR 10/02/2025 - 04:41 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.

Positive

• Director purchase of 3,916 shares reported, increasing insider holdings
• Transaction price disclosed: $3.83, providing a precise cost basis for the purchase
• Post-transaction beneficial ownership: 41,688 shares clearly stated

Negative

• None.

Insider Trade Summary

Grant/Award: 3,916 shares

Grant/Award 1 txn

Insider WHOLIHAN EDWARD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,916	$3.83	$15K

Holdings After Transaction: Common Stock — 41,688 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did KRMD director Edward Wholihan report?

He reported the purchase of 3,916 shares of KORU Medical Systems common stock on 10/02/2025.

At what price were the KRMD shares purchased in the Form 4?

The reported purchase price was $3.83 per share.

How many KRMD shares does the reporting person own after the transaction?

The Form 4 shows beneficial ownership of 41,688 shares following the reported transaction.

Who signed the Form 4 filing for Edward Wholihan?

The filing bears the signature of Thomas Adams as Attorney-in-Fact dated 10/02/2025.

What type of SEC form was filed for this insider transaction?

A Form 4 (Statement of Changes in Beneficial Ownership) was filed pursuant to Section 16.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

WHOLIHAN EDWARD

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NJ 07430

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		A		3,916	A	$3.83	41,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams- Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.